Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

Furmonertinib (AST2818) is a pan-EGFR tyrosine kinase inhibitor with central nervous system (CNS) antitumor activity. We report the CNS efficacy of furmonertinib compared with gefitinib in untreated EGFR-sensitizing mutation-positive NSCLC from the FURLONG study. FURLONG was a randomized, double-bli...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2022-11, Vol.17 (11), p.1297-1305
Hauptverfasser:	Shi, Yuankai, Chen, Gongyan, Wang, Xiang, Liu, Yunpeng, Wu, Lin, Hao, Yanrong, Liu, Chunling, Zhu, Shuyang, Zhang, Xiaodong, Li, Yuping, Liu, Jiwei, Cao, Lejie, Cheng, Ying, Zhao, Hui, Zhang, Shucai, Zang, Aimin, Cui, Jiuwei, Feng, Jian, Yang, Nong, Liu, Fei, Jiang, Yong, Gu, Chuan
Format:	Artikel
Sprache:	eng
Schlagworte:	AST2818 Carcinoma, Non-Small-Cell Lung - chemically induced Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Central Nervous System CNS Disease-Free Survival EGFR ErbB Receptors - genetics Furmonertinib Gefitinib - pharmacology Gefitinib - therapeutic use Humans Lung Neoplasms - chemically induced Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation NSCLC Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Quinazolines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!